Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/ebjiCfbwoceUvawRgkJl

  ADVERTISEMENT  
December 3, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
 
  • AATB appoints Wilton as new CEO
    The American Association of Tissue Banks has appointed Frank Wilton as its new CEO. Wilton formerly held a number of positions at AdvaMed. "I look forward to leading AATB during this time of important changes in the tissue industry and health care policy," Wilton said in a news release. "AATB honors donors, saves and improves lives by promoting the safety, quality, and availability of donated cells and tissue and I look forward to continuing this tremendous mission." American Association of Tissue Banks/News release (11/26) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
NEW Complement Coated C3 Control Cells!
Hemo bioscience has received FDA clearance for its complement coated control cells. Hemo bioscience C3 Control Cells can be used as a control to confirm the efficacy of the AHG reagent used during Direct and Indirect Anti-Globulin tests. For details regarding pricing, manufacturing schedule, and distribution channels email us or call 866-332-2835.

  Science & Health 
 
  • Chinese official says HIV/AIDS continues to be a challenge
    Chinese Vice Premier Li Keqiang said the increasing cases of HIV/AIDS in China continue to be a medical and social challenge. Data from the country points to the growing trend, with AIDS-related deaths increasing by 8.6% to 17,740, compared with figures from last year. The country has also reported 68,802 new HIV/AIDS cases up to October this year, according to Chinese state media. This may be lower than the number of actual cases since some cases may be undetected. CNN (12/1) LinkedInFacebookTwitterEmail this Story
  • Committee supports delay in umbilical cord clamping for preemies
    A 30- to 60-second delay in clamping the umbilical cord leads to better outcomes for preterm infants but research is less clear about the effects on term infants, according to an opinion by a committee of the American College of Obstetricians and Gynecologists with help from the American Academy of Pediatrics. The opinion said the most important benefit in preterm infants is an almost 50% reduced risk of intraventricular hemorrhaging. PhysiciansBriefing.com/HealthDay News (11/30) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Certified Quality Auditor Question Bank
Simulate the CQA exam from the convenience of your home or office. ASQ's online certification preparation course teaches you the concepts you'll see on your test, and provides practice exams so you can review the material. This gives you the best chance to learn effectively and pass your exam. All for as little as $99.

  Hot Topics 

Top five news stories selected by AABB SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Emerging Trends 
  • ACA to increase data managed by CMS
    CMS expects an increase in the Medicare and Medicaid data that it manages when the Affordable Care Act is fully implemented in 2015. By that year, data related to Medicare claims could nearly double and reach 700 terabytes, while Medicaid claims information could more than triple to 100 terabytes. The agency is focusing its efforts on using enterprise and shared services as well as developing the capabilities needed to gather, assess and leverage real-time data to address the challenge. Healthcare IT News (11/30) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 
  • CSL sees increase in demand for immunoglobulin products
    CSL has released improved guidance for 2013, expecting an increase in its profit. The Australian company said a major factor for this increase is the growing demand for its immunoglobulin products for immune deficiency disorders. U.S. demand is increasing at a 7% to 9% rate, according to the company. The Wall Street Journal (11/29) LinkedInFacebookTwitterEmail this Story
  • Auburn unveils vaccine platform for intracellular pathogens
    Auburn University veterinary school researchers have designed a novel vaccine platform for intracellular pathogens such as malaria and tuberculosis. Both humans and animals can benefit from vaccines based on this research, but developing the veterinary vaccine first is most efficient, according to lead researcher and veterinarian Bernhard Kaltenboeck. "The veterinary route is going to produce a much quicker return on a lower investment, versus human vaccine, that takes much longer to produce a return and is a much higher investment," Kaltenboeck said. Opelika-Auburn News (Ala.) (11/28) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  • FDA website may speed processing of med-tech export certificates
    The FDA Center for Devices and Radiological Health has unveiled a website designed to allow med-tech firms to file their requests for export documents electronically instead of using paper-based applications. The Export Certification & Tracking System is expected to cut the time it takes to process certificate requests and enable applicants to check status updates online in real time. MassDevice.com (Boston) (11/30) LinkedInFacebookTwitterEmail this Story
  • Grand jury begins probe of NECC
    A grand jury started investigating the New England Compounding Center, issuing subpoenas to former employees of the drug compounder and Medical Sales Management, a firm that provided administrative support and handled sales for NECC, the former workers say. Prosecutors are likely to focus on three charges: defrauding Medicaid or Medicare, committing fraud, and violating the Food, Drug and Cosmetic Act by selling tainted medicines. The Boston Globe (tiered subscription model) (12/1) LinkedInFacebookTwitterEmail this Story
  • House panel probes CMS anti-fraud efforts
    CMS has had some success in rooting out fraud and abuse but has not made use of all available tools, House Energy and Commerce Health Subcommittee members said last week. Speaking at a hearing, a WellPoint official outlined the company's efforts to track prescriptions for controlled substances that have reportedly saved "many millions of dollars." MedPage Today (free registration) (11/29) LinkedInFacebookTwitterEmail this Story
  Association News 
  • AABB issues Association Bulletin addressing donor screening policy related to XMRV and CFS
    The AABB Board of Directors has approved recommendations of the AABB Interorganizational XMRV Task Forces on Xenotropic Murine Leukemia Virus-Related Virus that address donor screening policy related to XMRV and other murine leukemia viruses and the absence of an association of these viruses to chronic fatigue syndrome. The content in Association Bulletin #12-05 supersedes information found in Association Bulletin #10-03. The association bulletin also links to an updated table of published studies on XMRV and MLV findings created and maintained by the Emerging Infectious Diseases subgroup of the AABB Transfusion-Transmitted Diseases Committee. LinkedInFacebookTwitterEmail this Story

Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
West Coast Account ManagerMacopharma USAUS - Nationwide
Director, LaboratorySan Diego Blood BankUS - CA - San Diego
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Help Desk SpecialistAABBUS - MD
Click here to view more job listings.

  SmartQuote 
Silent gratitude isn't much use to anyone."
--Gladys Bronwyn Stern,
British writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information